Radiotherapy complements immune checkpoint blockade

Shin Foong Ngiow; Grant A McArthur; Mark J Smyth

doi:10.1016/j.ccell.2015.03.015

Radiotherapy complements immune checkpoint blockade

Cancer Cell. 2015 Apr 13;27(4):437-8. doi: 10.1016/j.ccell.2015.03.015.

Authors

Shin Foong Ngiow¹, Grant A McArthur², Mark J Smyth³

Affiliations

¹ Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, QLD 4006, Australia; School of Medicine, University of Queensland, Herston, QLD 4006, Australia.
² Cancer Therapeutics Programs, Trescowthick Laboratories, Peter MacCallum Cancer Centre, St. Andrews Place, East Melbourne, VIC 3002, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC 3010, Australia.
³ Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, QLD 4006, Australia; School of Medicine, University of Queensland, Herston, QLD 4006, Australia. Electronic address: mark.smyth@qimrberghofer.edu.au.

PMID: 25873170
DOI: 10.1016/j.ccell.2015.03.015

Abstract

Adaptive immune resistance ablates effective anti-tumor immune responses. In a recent issue of Nature, Victor and colleagues describe that anti-PD-L1 combats adaptive immune resistance upon localized radiation plus anti-CTLA-4 therapy. The superior activity of radiation and dual immune checkpoint blockade is mediated by non-redundant immune mechanisms in cancer.

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Animals
B7-H1 Antigen / antagonists & inhibitors*
CTLA-4 Antigen / antagonists & inhibitors*
Cell Cycle Checkpoints / drug effects*
Female
Humans
Melanoma / drug therapy*
Melanoma / immunology*
Melanoma / radiotherapy*
T-Lymphocytes / drug effects*
T-Lymphocytes / radiation effects*

Substances

B7-H1 Antigen
CTLA-4 Antigen